Primary Immune Responses and Affinity Maturation Are Controlled by IgD.
B cell selection
IgD
IgM
antigen-valency
autoimmunity
tolerance
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
05
2021
accepted:
15
07
2021
entrez:
26
8
2021
pubmed:
27
8
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Mature B cells co-express IgM and IgD B cell antigen receptors (BCR) on their surface. While IgM BCR expression is already essential at early stages of development, the role of the IgD-class BCR remains unclear as most B cell functions appeared unchanged in IgD-deficient mice. Here, we show that IgD-deficient mice have an accelerated rate of B cell responsiveness as they activate antibody production within 24h after immunization, whereas wildtype (WT) animals required 3 days to activate primary antibody responses. Strikingly, soluble monovalent antigen suppresses IgG antibody production induced by multivalent antigen in WT mice. In contrast, IgD-deficient mice were not able to modulate IgG responses suggesting that IgD controls the activation rate of B cells and subsequent antibody production by sensing and distinguishing antigen-valences. Using an insulin-derived peptide we tested the role of IgD in autoimmunity. We show that primary autoreactive antibody responses are generated in WT and in IgD-deficient mice. However, insulin-specific autoantibodies were detected earlier and caused more severe symptoms of autoimmune diabetes in IgD-deficient mice as compared to WT mice. The rapid control of autoimmune diabetes in WT animals was associated with the generation of high-affinity IgM that protects insulin from autoimmune degradation. In IgD-deficient mice, however, the generation of high-affinity protective IgM is delayed resulting in prolonged autoimmune diabetes. Our data suggest that IgD is required for the transition from primary, highly autoreactive, to secondary antigen-specific antibody responses generated by affinity maturation.
Identifiants
pubmed: 34434193
doi: 10.3389/fimmu.2021.709240
pmc: PMC8381280
doi:
Substances chimiques
Autoantigens
0
Immunoglobulin D
0
Immunoglobulin G
0
Receptors, Antigen, B-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
709240Informations de copyright
Copyright © 2021 Amendt, Ayoubi, Linder, Allies, Young, Setz and Jumaa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Immunol. 2015 May;16(5):534-43
pubmed: 25848865
Proc Natl Acad Sci U S A. 1989 Oct;86(20):8039-43
pubmed: 2682636
Science. 2003 Sep 5;301(5638):1374-7
pubmed: 12920303
Front Immunol. 2017 May 31;8:603
pubmed: 28620373
Nature. 2010 Sep 23;467(7314):465-9
pubmed: 20818374
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3327-32
pubmed: 16492756
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1184-9
pubmed: 10655505
Proc Natl Acad Sci U S A. 2017 May 16;114(20):5231-5236
pubmed: 28461496
Trends Immunol. 2016 May;37(5):310-320
pubmed: 27052149
Curr Opin Rheumatol. 2009 Sep;21(5):465-70
pubmed: 19568172
Front Neurol. 2019 May 08;10:438
pubmed: 31139133
Sci Signal. 2015 Sep 15;8(394):ra93
pubmed: 26373673
J Immunol. 2013 Feb 1;190(3):987-96
pubmed: 23267023
Nature. 1988 Aug 25;334(6184):676-82
pubmed: 3261841
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):
pubmed: 33563755
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1602-6
pubmed: 6966401
Nat Commun. 2016 Nov 10;7:13381
pubmed: 27830696
Adv Immunol. 1989;44:93-151
pubmed: 2646863
J Immunol. 2016 Sep 15;197(6):2522-31
pubmed: 27534555
J Pediatr. 1980 Mar;96(3 Pt 1):417-20
pubmed: 7359233
Clin Exp Immunol. 2005 Jun;140(3):564-71
pubmed: 15932520
J Exp Med. 1992 Oct 1;176(4):991-1005
pubmed: 1402669
Curr Opin Rheumatol. 2007 Nov;19(6):523-9
pubmed: 17917530
EMBO J. 2019 Jun 3;38(11):
pubmed: 31015337
J Clin Invest. 2015 Jun;125(6):2194-202
pubmed: 25938780
Front Immunol. 2016 Mar 15;7:99
pubmed: 27014278
Curr Rheumatol Rep. 2003 Aug;5(4):311-6
pubmed: 14531959
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1887-91
pubmed: 8446604
Mol Immunol. 2000 Dec;37(18):1141-9
pubmed: 11451419
Nat Rev Dis Primers. 2016 Jun 16;2:16039
pubmed: 27306639
Nature. 1989 Feb 9;337(6207):562-6
pubmed: 2783762
Arthritis Res Ther. 2011;13(5):241
pubmed: 21989039
Elife. 2018 Mar 09;7:
pubmed: 29521626
J Immunol. 2016 May 15;196(10):4348-57
pubmed: 27183643
Eur J Immunol. 2018 Jul;48(7):1101-1113
pubmed: 29733429
Immunology. 2006 Aug;118(4):429-37
pubmed: 16895553
Blood Transfus. 2007 Nov;5(4):227-40
pubmed: 19204779
J Immunol. 2017 Nov 15;199(10):3387-3394
pubmed: 29109178
J Exp Med. 2020 Feb 3;217(2):
pubmed: 31727780
J Exp Med. 1978 Feb 1;147(2):582-7
pubmed: 304883
Immunity. 2018 Oct 16;49(4):709-724.e8
pubmed: 30291028
Front Immunol. 2016 Jun 06;7:198
pubmed: 27375614
Curr Opin Immunol. 2019 Dec;61:26-32
pubmed: 31445312
Int Immunol. 2004 May;16(5):675-84
pubmed: 15096487
Genes Cells. 2018 Oct;23(10):868-879
pubmed: 30092613
J Exp Med. 1993 Jan 1;177(1):45-55
pubmed: 8418208
J Immunol. 1998 May 15;160(10):4776-87
pubmed: 9590224
Nat Immunol. 2017 Mar;18(3):321-333
pubmed: 28135254
Nature. 2012 Sep 6;489(7414):160-4
pubmed: 22902503
J Exp Med. 2000 Apr 3;191(7):1253-8
pubmed: 10748243
Sci Rep. 2016 May 16;6:25629
pubmed: 27181049
Nature. 1989 Nov 23;342(6248):385-91
pubmed: 2586609